| Date | Title | Description |
| 12.12.2021 | I-MAB Biopharma and AGC Biologics Partner on Late-Phase Project | AGC Biologics today announced a new partnership with I-MAB Biopharma (Nasdaq: IMAB). The I-MAB treatment being developed is approaching late-phase clinical trials and AGC Biologics will manufacture the materials at its site in Seattle, whil... |
| 07.12.2021 | AGC Biologics Receives Transatlantic Award for Investments in Milan Biopharmaceutical Industry | AGC Biologics today announced it won the 2021 Transatlantic Award from the American Chamber of Commerce in Italy (AmCham). The company was named the 2021 winner for its investments in the Italian biopharmaceutical industry, which includes e... |
| 01.12.2021 | 4TEEN4 Pharmaceuticals Selects AGC Biologics to Manufacture Procizumab | AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) to manufacture and commercialize Procizumab. The fir... |
| 13.09.2021 | AGC Biologics Expands pDNA and mRNA Manufacturing Capacity | AGC Biologics today announced expansion plans for the company’s Heidelberg facility to increase manufacturing capacities for plasmid-DNA (pDNA) and messenger RNA (mRNA) projects.
With this expansion, AGC Biologics is boosting its current 1... |
| 20.08.2021 | AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site | AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new facility at its Copenhagen, Denmark site. This multipurpose facility will allow AGC Biolog... |
| 17.08.2021 | Norgine B.V. completes important regulatory milestone for ANGUSTA® (misoprostol) in Europe for oral induction of labour | Norgine B.V. (Norgine) today announced the successful completion of the Repeat Use Procedure (RUP) for ANGUSTA® in a number of European countries including Austria, Belgium, Cyprus, Germany, Greece, Spain, Ireland, Italy, Luxemburg, Malta, ... |
| 19.04.2021 | Bactolife raises EUR 7 million in Seed financing | Novo Seeds, the early stage investment and company creation team of Novo Holdings, today announced that it is leading a EUR 7 million seed investment into Bactolife™, a Danish start-up developing novel biological solutions to reduce the ris... |
| 19.02.2019 | AGC Biologics A/S and Calypso Biotech BV Announce Agreement for Process Development and cGMP Manufacture of CALY-002 | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, and Calypso Biotech B.V. (Calypso), a biotechnology company focused on the development of novel therapeutic antibodies in the inflammation/auto... |
| 21.09.2018 | AGC Biologics Adds Mammalian Production Capacity in Japan | New facility will include comprehensive mammalian process development and manufacturing capabilities
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its ongoi... |
| 22.08.2018 | AGC Biologics Expands Capacity at Copenhagen, Denmark Facility | Strategic expansion will meet increasing global demand for biopharmaceutical development and manufacturing
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that as part of its... |
| 25.07.2018 | AGC Biologics Inaugurates New Global Headquarters Facility in Bothell, WA | Ribbon Cutting Ceremony Held to Commemorate Company Milestone
AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, celebrated the opening of the company’s new Global Headquarters facility in Both... |
| 24.05.2018 | AGC Biologics Cleared for Commercial Manufacture of Portola's FDA-Approved Andexxa® | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that it will supply bulk drug substance for the launch of Portola Pharmaceuticals' Andexxa® [coagulation factor Xa (recombinant... |
| 10.05.2018 | AGC Biologics enters into Commercial Supply Agreement with MacroGenics | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that in late 2017 it entered into a commercial supply agreement with MacroGenics, a clinical-stage biopharmaceutical company fo... |
| 03.05.2018 | AGC Biologics enters into Commercial Manufacturing Agreement with Horizon Pharma plc | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today it has entered into an agreement with Horizon Pharma plc for commercial supply of teprotumumab, a monoclonal antibody biologic ... |
| 23.04.2018 | Polyvac® Peanut CMO appointed | Allergy Therapeutics plc (AIM:AGY), the fully integrated specialty pharmaceutical group specialising in allergy vaccines, today announces it has signed a contract with AGC Biologics (Heidelberg, Germany) to scale up the manufacturing of its... |
| 29.03.2018 | AGC Biologics Increases Footprint in Bothell, WA | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the addition of a new building complex that will house the company’s global headquarters in Bothell, Washington.
The new compl... |
| 06.03.2018 | AGC Biologics Expands Capacity at Berkeley, California Facility | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today that their Berkeley, California facility is adding to its growing capacity with the addition of a 2000L single-use bioreactor (... |
| 22.01.2018 | AGC Biologics to Hold Technical Seminar in Taiwan | AGC Biologics, a global leader in clinical and commercial manufacturing of therapeutic proteins, announced today the company will hold a technical seminar in Taipei City, Taiwan, exclusively focused on early-phase development and manufactur... |
| 08.01.2018 | AGC Bioscience, Biomeva, and CMC Biologics to provide services under the brand AGC Biologics | AGC Biologics, a convergence of Asahi Glass Company (AGC) Bioscience, Biomeva GmbH, and CMC Biologics, announced today that effective January 8, 2018, the company will be integrated and newly branded as AGC Biologics.
AGC Biologics, a glob... |
| 18.12.2017 | Angusta® is now approved in 16 EU countries | Azanta, a Danish specialty pharmaceutical company dedicated to women’s health, is granted Marketing Authorisation for Angusta® in an additional 11 European countries including France.
Azanta announces that a Marketing Authorisation has bee... |
| 12.12.2017 | CMC Biologics Announces Development and Manufacturing Agreement with Harpoon Therapeutics | CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Harpoon Therapeutics, an immuno-oncology company using its proprietary TriTAC™ technology platform to discover... |
| 22.08.2017 | CMC Biologics and Aptevo Therapeutics Enter into Commercial Manufacturing Agreement for IXINITY® | CMC ICOS Biologics, Inc., a global leader in clinical and commercial manufacturing of monoclonal antibodies, coagulation factors and other therapeutic proteins, and Aptevo Therapeutics (Nasdaq: APVO), a biotechnology company focused on deve... |
| 22.07.2017 | CMC Biologics Enters into Development and Manufacturing Agreement with Trellis BioScience | Development of Trellis’ monoclonal antibody (mAb) using CMC Biologics’ proprietary CHEF1® Expression Platform and Multi-column Continuous Chromatography (MCC) Technology
CMC ICOS Biologics, Inc., a global leader in clinical and commercial ... |
| 13.04.2017 | Altor BioScience and CMC Biologics Announce Agreement for Manufacture and Validation of Altor’s IL-15 Superagonist Molecule, ALT-803, for use in Phase 3 Clinical Trials | CMC ICOS Biologics, Inc. (“CMC Biologics”), a global leader in clinical and commercial manufacturing of therapeutic proteins, and Altor BioScience Corporation (“Altor”), a leading developer of novel cytokine-based immunotherapeutics for can... |
| 14.03.2017 | Appointment of new Azanta CEO and market launch of Angusta | Wolfgang Amann, former Head of Sobi’s commercial operations in the German Speaking European Countries, to Take Helm.
Angusta now available for all women requiring induction of labour in the Nordic Countries.
Azanta A/S (“Azanta”), a speci... |